Oncology Competitor Counter-Detail Builder
Generate evidence-based competitive rebuttals for oncology sales conversations instantly.
What You Can Do
You can rapidly construct evidence-based competitive responses that address specific oncologist objections with clinical parity analysis, head-to-head trial comparisons, and safety contextualization. The skill generates 2-3 minute talking points that distinguish your oncology drug on meaningful endpoints while flagging claims requiring medical science liaison support or printed evidence—ensuring your counter-details hold up to regulatory scrutiny without crossing into prohibited promotional territory.
Features
Side-by-side comparison of your drug versus competitor on efficacy endpoints, progression-free survival, overall survival, and response rates for specific patient populations
Automatic flagging of claims requiring medical science liaison escalation, printed evidence support, or REMS documentation before delivery
Identifies which patient subgroups benefit most from your drug and which may be better served by competitor options, supporting ethical positioning
Frames efficacy within the unique safety monitoring, pharmacovigilance, and access requirements of your drug versus competitor alternatives
Structures rebuttals around published pivotal trials, real-world evidence studies, and guideline positioning with specific data point citations
Generates speaking points for competitive scenarios in multi-specialty team settings with oncologist, pathologist, and other stakeholder objections pre-addressed
Incorporates post-market effectiveness data, observational studies, and registry data to support efficacy claims beyond pivotal trial populations
Example Output
Example 1 — Response to KEYNOTE Trial Objection
Doctor says: "Your competitor's KEYNOTE study showed a 40% response rate. Yours was only 32%."
Your counter-detail: "The KEYNOTE population was PD-L1 positive, high-burden disease. In our head-to-head Phase 3 subgroup of PD-L1 positive patients, response rates were comparable at 38%, but our median progression-free survival was 14.2 months versus 11.8 months in their data. Plus, their REMS program requires monthly imaging for safety monitoring—our protocol allows quarterly assessments once stable, which improves real-world adherence."
Example 2 — REMS Complexity Objection
Doctor says: "Your competitor's REMS is simpler. We're thinking of switching."
Your counter-detail: "I understand—REMS burden matters to your infusion center. Ours does require baseline and periodic liver monitoring, but that overlaps with standard care panels for oncology patients anyway. What's different: our real-world data from 2,400 patients showed 94% completion rates because monitoring integrated into routine labs. Their simpler REMS reflects a different safety profile—more baseline hepatotoxicity events in trials. Happy to connect our medical science team to review your specific workflow and see where we can streamline."
Example 3 — Patient Population Qualifier
Doctor says: "Should I use your drug or their drug for this BRCA-wild-type patient?"
Your counter-detail: "Great question. For BRCA-wild-type patients, our data shows best benefit in those with high mutational burden—median OS benefit is 5.2 months. Their drug showed stronger benefit in BRCA-mutant patients, around 7 months OS improvement. For your specific patient, I'd actually lean toward their option based on the tumor profile we discussed. But if you see a high-burden wild-type patient next, ours typically outperforms in our real-world cohort."
What's Included
- SKILL.md instruction file: Complete framework for structuring competitive responses with compliance checkpoints
- Clinical parity comparison template: Side-by-side trial data structure for efficacy, safety, and REMS comparison
- Compliance guardrail checklist: Flags claims requiring MSL escalation, printed evidence, or additional regulatory support
- Patient population qualifier workflow: Decision tree for identifying which patient subgroups fit your drug versus competitor alternatives
- Tumor board talking point template: Pre-built responses for common multi-specialty objections with citations
Who It's For
- Oncology field sales representatives responding to real-time competitive objections during office visits
- Regional or territory managers preparing account teams for high-risk accounts with competitor market share
- Inside sales specialists supporting external reps with rapid competitive intelligence during Zoom or phone calls
- Medical science liaisons briefing field teams before tumor board presentations or clinical advisory board meetings
- New oncology reps building confidence in competitive positioning during early-career ramp
Best For
- Real-time competitive rebuttals during oncologist objections in office or virtual settings
- Pre-visit account planning for known competitive threats or switching risk
- Tumor board preparation where multiple competing drugs will be discussed
- Published trial or guideline objection responses requiring clinical evidence grounding
- Patient population qualification conversations to identify best-fit candidates for your drug
You might also like
You systematically evaluate incoming pharmaceutical contracts—from payers, healthcare systems, pharmacy chains, and specialty distributors—to surface pricing vulnerabilities, market access constraints, and negotiation leverage points before signing. Using a four-layer assessment model covering structural, access, compliance, and commercial risks, you transform 2–4 hours of manual contract review into a 20–30 minute structured analysis that protects margin and builds evidence-based negotiation strategies.
by killvault
You can convert raw clinical and mechanistic immunology data into structured evidence packages tailored for specific audiences and conversation objectives. This skill maps intricate immune mechanisms into audience-appropriate explanations, connects clinical trial results back to underlying immunological targets, and builds defensible narratives with embedded evidence anchors and citations. The output is a conversation-ready package that anticipates questions and provides mechanistically grounded responses while maintaining compliance with data source tracking.
by killvault
You can rapidly extract and validate key claims from manufacturer HEOR dossiers (typically 200+ pages), assess cost-effectiveness calculations against payer willingness-to-pay thresholds, identify evidence gaps and potential bias, and generate formulary recommendations with documented rationale for P&T committee review. This framework reduces typical 3-5 hour manual analysis to 90 minutes of focused, traceable review.
by killvault
You can rapidly transform peer-reviewed clinical data, real-world evidence, and trial results into Congressional-grade policy documents that speak directly to legislative priorities—cost, access, public health, innovation, and safety. This skill enables you to respond to Congressional inquiries, assess legislative threats and opportunities, and develop evidence-backed advocacy positions without crossing into prohibited promotion or losing scientific credibility.
by killvault
You can upload consortium license agreements, operating agreements, and partnership contracts to receive detailed clause-by-clause analysis, risk assessments, and negotiation strategies. The skill identifies ambiguous terms, extracts member obligations and rights, flags legal and financial risks, and suggests targeted redline language specific to consortium structures. You get actionable negotiation talking points and a prioritized risk summary ready for your legal team.
by killvault
Generate compelling strategic plans, funding cases, and advocacy materials that demonstrate library value to stakeholders and secure community support. Create data-backed narratives, detailed budget justifications, and presentation materials that align library services with community needs and foundation priorities. Produce board-ready documents and grant proposals that position your library as essential infrastructure.
by killvault
Automatically classify corporate records by retention requirements, legal hold status, and regulatory compliance needs. Claude generates audit-ready documentation that demonstrates proper record management and ensures your organization meets document retention policies and regulatory requirements across GDPR, SOX, HIPAA, and industry-specific frameworks.
by killvault
You can automatically create standardized metadata schemas and rich descriptions for digital archive items. This skill generates Dublin Core-compliant or custom metadata structures, writes contextual descriptions with preservation notes, and organizes large collections with consistent, searchable metadata that improves discoverability and long-term preservation.
by killvault